All In Biotech

Drug Trial Radar · NCT06887192

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Hallucinations and Delusions Associated With Alzheimer's Disease Psychosis

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Aug 15, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
MapLight TherapeuticsIndustry
Sponsor type
Industry
First posted
Mar 20, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ML-007C-MA-221 is a Phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ML-007C-MA in male and female participants aged 55 to 90 years with hallucinations and delusions associated with Alzheimer's Disease Psychosis (ADP). The primary objective is to evaluate the efficacy of ML-007C-MA compared with placebo for the treatment of hallucinations and delusions associated with ADP as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

Conditions

  • Psychosis Associated With Alzheimer's Disease

Interventions

  • ML-007C-MADrug

    ML-007C-MA dosed as 105/1.5 mg BID, or 210/3 mg BID

  • PlaceboDrug

    Placebo Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline to End of Treatment in the Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions (NPI-C H+D) scoreTime frame: Baseline and End of Treatment (7 weeks)

Locations

69 sites in 15 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Phoenix, Arizona · Recruiting

  • Clinical Site

    Scottsdale, Arizona · Recruiting

  • Clinical Site

    Tucson, Arizona · Recruiting

  • Clinical Site

    Anaheim, California · Recruiting

  • Clinical Site

    Long Beach, California · Recruiting

  • Clinical Site

    Murrieta, California · Recruiting

  • Clinical Site

    Orange, California · Recruiting

  • Clinical Site

    Redlands, California · Recruiting

  • Clinical Site

    San Diego, California · Recruiting

  • Clinical Site

    Denver, Colorado · Recruiting

  • Clinical Site

    Boca Raton, Florida · Recruiting

  • Clinical Site

    Deerfield Beach, Florida · Recruiting

  • Clinical Site

    Doral, Florida · Recruiting

  • Clinical Site

    Homestead, Florida · Recruiting

  • Clinical Site

    Miami, Florida · Recruiting

  • Clinical Site

    Miami, Florida · Recruiting

  • Clinical Site

    Miami, Florida · Recruiting

  • Clinical Site

    Miami, Florida · Recruiting

  • Clinical Site

    Miami Gardens, Florida · Recruiting

  • Clinical Site

    Miami Gardens, Florida · Recruiting

  • Clinical Site

    Naples, Florida · Recruiting

  • Clinical Site

    Orlando, Florida · Recruiting

  • Clinical Site

    Tampa, Florida · Recruiting

  • Clinical Site

    West Palm Beach, Florida · Recruiting

  • Clinical Site

    Augusta, Georgia · Recruiting

  • Clinical Site

    Snellville, Georgia · Recruiting

  • Clinical Site

    Alexandria, Louisiana · Recruiting

  • Clinical Site

    Las Vegas, Nevada · Recruiting

  • Clinical Site

    West Long Branch, New Jersey · Recruiting

  • Clinical Site

    New York, New York · Recruiting

  • Clinical Site

    Dayton, Ohio · Recruiting

  • Clinical Site

    Independence, Ohio · Recruiting

  • Clinical Site

    Tigard, Oregon · Recruiting

  • Clinical Site

    Port Royal, South Carolina · Recruiting

  • Clinical Site

    Austin, Texas · Recruiting

  • Clinical Site

    McKinney, Texas · Recruiting

  • Clinical Site

    Sugarland, Texas · Recruiting

  • Clinical Site

    Bellevue, Washington · Recruiting

  • Clinical Site

    Córdoba, Argentina · Recruiting

  • Clinical Site

    La Plata, Buenos Aires, Argentina · Recruiting

Showing 40 of 69 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.